Rewriting Biology.
Healing at the Source.
Zenth's gene therapy division leverages precision genome editing, advanced vector engineering, and AI-driven target discovery to develop permanent curative treatments for genetic, oncologic, and neurodegenerative diseases.
Next-Generation Therapeutic Engineering
Operating under Zenth Health Sciences, our gene therapy platform integrates molecular biology, computational genomics, and clinical translation to accelerate the development of FDA/EMA-compliant genetic interventions. With 14 active programs across 9 global manufacturing sites, we are advancing from experimental vectors to scalable, patient-ready therapies.
Therapeutic Modalities
CRISPR-Cas9 & Base Editing
High-fidelity programmable nucleases enabling precise single-nucleotide corrections and epigenetic modulation without double-strand breaks.
Active in 6 ProgramsAAV Vector Engineering
Capsid-shielded adeno-associated viruses optimized for tissue-specific transduction, reduced immunogenicity, and enhanced payload capacity.
Phase II/III ReadyLNP & Exosome Delivery
Next-generation lipid nanoparticles and engineered exosomes enabling systemic mRNA delivery, organ targeting, and blood-brain barrier penetration.
Preclinical → Phase IEpigenetic Reprogramming
Non-genomic modulation of chromatin states to silence pathogenic alleles, reactivate therapeutic genes, and restore cellular homeostasis.
Discovery StageClinical & Preclinical Programs
| Program Name | Indication | Modality | Status | Region |
|---|---|---|---|---|
| ZNT-402 (HemAegis) | Beta-Thalassemia | Ex vivo CRISPR | Phase III | NA / EU |
| ZNT-118 (NeuroSilence) | Huntington’s Disease | AAV-ASO | Phase II | Global | d>
| ZNT-887 (OncoVector) | Refractory Solid Tumors | Conditionally Replicative Virus | Phase I/II | APAC / EU |
| ZNT-009 (RetinaRestore) | Leber Congenital Amaurosis | RPE65 Gene Addition | Market Access | NA / EU / JP |
| ZNT-551 (CardioGuard) | Cardiomyopathy (HCM) | mRNA LNP | Phase II | NA |
Ethical Innovation. Rigorous Oversight.
Zenth's gene therapy research adheres to the highest international standards of bioethics, patient safety, and regulatory compliance. Every program undergoes multi-stage review by our independent Bioethics Advisory Board, institutional review boards (IRBs), and global health authorities before advancing to human trials.
Key Commitments
- ICH-GCP and FDA/EMA regulatory alignment across all phases
- Long-term follow-up protocols (15-year patient tracking)
- Germline editing prohibition policy (strictly somatic focus)
- Transparent adverse event reporting & data sharing
- Equitable access frameworks for emerging markets
Safety Metrics
Continuous monitoring of vector integration, immune response, and off-target effects using proprietary NGS profiling and AI-driven risk modeling.
Collaborate with Zenth Health Sciences
Whether you're a clinical partner, academic researcher, or potential trial participant, our team provides transparent access to program data, partnership frameworks, and regulatory guidance.